In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 23, No. 9 ( 2003-09), p. 1697-1702
Abstract:
Objective— Activated platelets rapidly adhere to monocytes and upregulate the expression of tissue factor (TF), the major trigger of the coagulation cascade. In this study, we examined the effect of abciximab, a nonselective glycoprotein IIb/IIIa-receptor antagonist, on monocyte TF expression in thrombin receptor activator–stimulated whole blood in vitro. Methods and Results— Abciximab (50 μg/mL) reduced the mass of platelets attached to monocytes, measured by the mean fluorescence intensity (MFI) of CD42b on CD14 + cells, 1 (CD42b, 471±197 versus 1073±217 MFI, mean±SD, P 〈 0.05), 5, and 10 minutes after thrombin receptor activator stimulation of whole blood to the same extent as anti–P-selectin (50 μg/mL; 288±177 MFI, P 〈 0.05) when determined by flow cytometry. In parallel, the expression of the platelet activation marker P-selectin colocalized with CD14 + monocytes was reduced up to 25% by abciximab at the same time points. Expression of monocyte TF antigen (CD14 + /TF + , 39.9±8.7% versus 66.3±19.9%, P 〈 0.05), chromogenic TF-activity (TF, 8.4±1.9 versus 13.2±2.8 U, arbitrary units, P 〈 0.05), and TF mRNA was suppressed in the presence of abciximab as a consequence of reduced platelet mass attached to monocytes. Conclusions— Our data suggest that heterotypic monocyte-platelet aggregates are a target for abciximab, which suppresses monocyte TF because of a reduction of monocyte-platelet cross talk.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/01.ATV.0000087035.46547.89
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2003
detail.hit.zdb_id:
1494427-3
Permalink